Skip to content

Study to Assess the Effect of Darbepoetin Alfa Injection in Addition to Standard Treatment in Patients with Diabetic Foot Ulcer

Evaluation of Subcutaneous Darbepoetin Alfa as an Add-On Therapy to Standard Care in Patients with Diabetic Foot Ulcer: a Randomized Open Label Parallel Group Prospective Study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096513
Enrollment
44
Registered
2025-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Subcutaneous Darbepoetin Alfa: Participants will receive subcutaneous darbepoetin alfa, 25 micrograms once weekly for 12 weeks, in addition to standard care including wound management,

Sponsors

syed nilufar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with Diabetes mellitus type -2 Presence of Wagner grade 1 or grade 2-foot ulcer

Exclusion criteria

Exclusion criteria: Active osteomyelitis or a history of osteomyelitis resolved within the last 4 weeks Presence of active gangrene at the time of screening History of solid tumors within the past 5 years History of hematological malignancies within the past 2 years Prior use of erythropoiesis-stimulating agents within the last 3 months Any history of pure red cell aplasia History of thromboembolic events within the past 6 months History of stroke or transient ischemic attack within the past 6 months Uncontrolled hypertension, defined as systolic greater than 160 mm hg or diastolic greater than 100 mm hg on atleast two readings taken one week apart Baseline hemoglobin concentration greater than 13mg per dl Pregnant women Lactating women

Design outcomes

Primary

MeasureTime frame
Change in wound size from baseline through weeks 4, 8, and 12, measured using the manual length-width method in centimetersTimepoint: weeks 4, 8, and 12

Secondary

MeasureTime frame
Incidence of adverse events related to darbepoetin alfa or standard careTimepoint: Throughout study, baseline to week 12;Change in HbA1c from baseline to end of treatment at 12 weeksTimepoint: Baseline, Week 12;Change in haemoglobin levels in intervention group, measured at screening, weeks 2, 4, 6, 8, 10, and 12Timepoint: Screening, Week 2, 4, 6, 8, 10, 12 ;Change in granulation tissue formation at baseline, week 4, 8, and 12Timepoint: Baseline, Week 4, Week 8, Week 12

Countries

India

Contacts

Public ContactDR S Seethalakshmi

ESIC Medical college and hospital

seethapharmacology@gmail.com6369702539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026